Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of reviewRecipients of solid organ transplants (SOTs) suffer a significant burden of invasive fungal infections (IFIs). The emergence of drug-resistant fungi and toxicities of currently used antifungal agents as well as drug-drug interactions with immunosuppressants make their treatment challenging. This review discusses selected novel antifungal agents in the development pipeline that can currently be used through clinical trials or may be commercially available in the near future.Recent findingsThese agents in development have novel pharmacokinetics and pharmacodynamics, expanded spectra of activity and excellent safety profiles.SummaryThe properties of novel antifungal agents have the potential to expand the therapeutic options for IFIs in recipients of SOTs.

Original languageEnglish
Pages (from-to)235-242
Number of pages8
JournalCurrent opinion in organ transplantation
Volume27
Issue number4
DOIs
StatePublished - Aug 1 2022

Keywords

  • antifungal drugs
  • invasive fungal infection
  • solid organ transplant

Fingerprint

Dive into the research topics of 'Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients'. Together they form a unique fingerprint.

Cite this